Eli Lilly stock rises about 7% in a week as regulators back key cancer drug and Medicare expands GLP-1 coverage

Eli Lilly’s stock climbed about 6.7% over the past week, a move traders tied to two distinct catalysts: expanding regulatory momentum for Jaypirca in Europe and a U.S. reimbursement pathway that broadens access to weight-loss and diabetes-related GLP-1 medicines under Medicare. The rally pushed Lilly shares to a new 52-week high on June 26, according to the market recap. Over the past year, the stock was up 53.7%, and the report described Lilly as the largest drugmaker by market value, trading above $1,000 per share and valued at more than $1 trillion. In Europe, the company’s Jaypirca (pirtobrutinib) received a positive step from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). CHMP recommended approval for Jaypirca for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy, including patients regardless of whether they previously received a BTK inhibitor, the report said. If the European Commission grants approval, the indication in the European Union would expand beyond Jaypirca’s current use, with a final decision expected within the process timeline described as within one to two months in the recap. The second catalyst centered on Medicare coverage. Lilly also announced additional details of its Medicare GLP-1 Bridge program, which the recap described as enabling eligible Medicare Part D beneficiaries to access its newly launched once-daily oral GLP-1 pill, Foundayo (orforglipron), along with its blockbuster GLP-1 injection, Zepbound (tirzepatide), for obesity. The program’s start date was July 1, 2026, with a price of $50 per month with prior authorization, and it is scheduled to run through December 31, 2027. For context, Medicare Part D is the prescription drug benefit for people enrolled in Medicare, and “prior authorization” means patients (or their clinicians) must obtain approval from the insurer before coverage begins. The report characterized the Medicare GLP-1 Bridge pathway as the first broad coverage route under Medicare Part D for GLP-1 obesity medicines for patients who meet CMS clinical criteria. While the market commentary pointed to these steps as reasons behind the stock’s strength, it did not offer new guidance from Lilly’s senior management about future revenue or profit, nor did it provide a full valuation discussion beyond broad references to premium positioning. For investors and analysts, the near-term question is how quickly expanded access and indication breadth translate into measurable demand, and whether uptake matches the pace implied by the stock move. The company’s public disclosures tied to these catalysts were summarized in the recap, but several specifics remain unclear from the information available for this story. The recap did not detail the exact CHMP opinion wording beyond the “all lines of therapy” expansion, and it did not break out expected utilization, Medicare eligibility estimates, or the financial terms beyond the stated $50-per-month figure for covered patients. It also did not quantify how much of the weekly price move is attributable to each catalyst versus broader sector sentiment. Looking ahead, investors will likely watch for the European Commission’s decision on Jaypirca’s expanded CLL indication and for early performance indicates from the Medicare program as it begins July 1, 2026. Any updates around reimbursement rules, formulary inclusion, or real-world prescribing patterns could become new drivers of volatility, particularly given Lilly’s high market valuation and the market’s sensitivity to GLP-1 demand assumptions.

keyFacts

whyItMatters

companies

tickers

sector

sourceTrail

confidence

needsReview